A pivotal phase III study of inhaled xenon for neuroprotection in out-of-hospital cardiac arrest (OHCA) patients

Trial Profile

A pivotal phase III study of inhaled xenon for neuroprotection in out-of-hospital cardiac arrest (OHCA) patients

Planning
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Xenon (Primary)
  • Indications Chronic brain damage
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2016 New trial record
    • 15 Mar 2016 NeuroproteXeon is seeking approval from the United States Food & Drug Administration (FDA) to launch this pivotal Phase III OHCA clinical study beginning later this year, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top